Literature DB >> 10366565

The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice.

M B Parr1, E L Parr.   

Abstract

We investigated the role of interferon gamma (IFN-gamma) in a mouse model of immunity to vaginal infection by herpes simplex virus type 2 (HSV-2). Within 8 h after immune mice were challenged intravaginally with HSV-2, IFN-gamma concentrations in vaginal secretions reached levels that can be antiviral in vitro. This rapid synthesis of IFN-gamma occurred in immune-challenged mice but not in nonimmune-challenged mice, indicating that it required memory T cells. Immunostaining and in situ hybridization revealed that the IFN-gamma was synthesized by cells whose morphological appearance suggested that they were lymphocytes and macrophage-like cells in the mucosa. The presence of IFN-gamma in vaginal secretions was correlated with upregulation of MHC class II antigens in the epithelium and with vigorous (30-fold) recruitment of T and B lymphocytes into the vagina. In vivo administration of anti-IFN-gamma to immune mice 17 h before virus challenge blocked the subsequent appearance of IFN-gamma in vaginal secretions, blocked upregulation of class II antigens, blocked adherence of T cells to endothelium and their recruitment into the vagina, and markedly reduced immunity against reinfection of the vaginal epithelium. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366565     DOI: 10.1006/viro.1999.9739

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

Authors:  E L Parr; M B Parr
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

3.  Differential polarization of immune responses by genetic cotransfer of chemokines changes the protective immunity of DNA vaccine against pseudorabies virus.

Authors:  Hyun A Yoon; Seong Kug Eo
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

4.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 5.  Dendritic cells and macrophages in the genitourinary tract.

Authors:  N Iijima; J M Thompson; A Iwasaki
Journal:  Mucosal Immunol       Date:  2008-09-10       Impact factor: 7.313

Review 6.  Tissue instruction for migration and retention of TRM cells.

Authors:  Norifumi Iijima; Akiko Iwasaki
Journal:  Trends Immunol       Date:  2015-08-14       Impact factor: 16.687

7.  Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.

Authors:  K Olson; P Macias; S Hutton; W A Ernst; G Fujii; J P Adler-Moore
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

8.  Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.

Authors:  Alison J Johnson; Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2009-11-25       Impact factor: 4.054

9.  Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus.

Authors:  Norifumi Iijima; Melissa M Linehan; Melodie Zamora; Debbie Butkus; Robert Dunn; Marilyn R Kehry; Terri M Laufer; Akiko Iwasaki
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

10.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.